Gene
ZNRF3
ZNRF3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Trial mentions (2), Target-disease associations (275), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ZNRF3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
ZNRF3 has 2 trial mentions across 2 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 1 of 11,460 | 0.01% |
| 2022 | 0 of 8,285 | 0.00% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 5 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 0 of 14,459 | 0.00% |
| 2019 | 1 of 7,300 | 0.01% | 1 of 12,159 | 0.01% |
| 2018 | 0 of 6,927 | 0.00% | 3 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 1 of 11,595 | 0.01% |
Showing 10 of 37 years.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ZNRF3 oncogenic mutation | Porcupine Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (2)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03833700 | Trial eligibility (AACT) |
| NCT05761951 | Trial eligibility (AACT) |
Target-disease associations (275)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| Abdominal Aortic Aneurysm | cardiovascular disease | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Aniridia-intellectual disability syndrome | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 275 associations.
Vendor sourcing (16)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Canonic... | View ClinVar record SCV006585359.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1882C>T (p.P628S) alteration is located in exon 8 (coding exon 8) of the ZNRF3 gene. This alteration results from a C to T substitution at nucleotide p... | View ClinVar record SCV003535618.3 |
| Cypherpunk Technologies Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the subject prior to performing any protocol-rel... | View trial NCT05761951 |
| Cypherpunk Technologies Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | ZNRF3 | View trial NCT05761951 |
| Eisai (Japan) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Participants with a histological and/or cytological diagnosis of solid tumor must have any of the following tumor types: 1. Dose Escalation Part: P... | View trial NCT03833700 |
Showing 5 of 16 sourcing records.
Trial-cited literature (22)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. | Signal transduction and targeted therapy | 2022 | 2,107 |
| Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. | Endocrine pathology | 2022 | 269 |
| Understanding and Harnessing Epithelial‒Mesenchymal Interactions in the Development of Palmoplantar Identity. | The Journal of investigative dermatology | 2022 | 7 |
| Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. | Signal transduction and targeted therapy | 2021 | 634 |
Showing 5 of 22 papers.
Literature-extracted relations (3)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Adrenocortical Carcinoma | Disease | associate |
Integrated genomic characterization of adrenocortical carcinoma. | 2014 |
| Ectodermal Dysplasia | Disease | associate |
Integrated genomic characterization of adrenocortical carcinoma. | 2014 |
| Neoplasms | Disease | inhibit |
Integrated genomic characterization of adrenocortical carcinoma. | 2014 |
Organizations publishing (74)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| University of Washington | Academic | 3 | 2015 to 2018 |
| Assistance Publique – Hôpitaux de Paris | Hospital | 2 | 2014 to 2015 |
| Central South University | Academic | 2 | 2022 to 2023 |
| Dana-Farber Cancer Institute | Other | 2 | 2015 to 2018 |
| Harris Health System | Hospital | 2 | 2014 to 2018 |
Showing 5 of 74 organizations.
Where ZNRF3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
260 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, protein variant mentions, and human sample screening reference.